The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.
Open accessAbstract
Twenty-five patients with stage IV melanoma were immunized with the mouse anti-idiotypic monoclonal antibody (mAb) MK2-23 (2 mg per injection), which bears the internal image of the determinant defined by anti-HMW-MAA mAb 763.74. Two patients were inevaluable, since they did not complete 4 weeks of therapy. Only 14 patients developed antibodies that were shown by serological and immunochemical assays to recognize the same or spatially close determinant as the anti-HMW-MAA mAb 763.74 and to express the idiotope defined by mAb MK2-23 in their antigen-combining sites. Side effects that are likely to be caused by bacillus Calmette-Guérin present in the immunogen consisted of erythema, induration, and ulceration at the sites of the injections. Occasionally, patients complained of flu-like symptoms, arthralgias, and myalgias. Three of the patients who developed anti-HMW-MAA antibodies achieved a partial response. It consisted of a decrease in the size of metastatic lesions and lasted 52 weeks in 1 patient and 93 weeks in the other 2 patients. Survival of the 14 patients who developed anti-HMW-MAA antibodies was significantly (P = 0.0003) longer than that of the 9 patients without detectable humoral anti-HMW-MAA immunity development. In the multivariate analysis, such an association between development of anti-HMW-MAA antibodies and survival prolongation was still significant (P = 0.001) after adjustment for difference in performance status, the only confounding factor found to be significantly related to survival. Lastly, a significant (P = 0.03 by likelihood ratio test) interaction between anti-HMW-MAA antibodies and patients' performance status was found, since the prolongation of survival associated with anti-HMW-MAA antibodies was more marked in patients with a performance status of less than or equal to 70% than in those with a higher one. These results suggest that anti-idiotypic mAb MK2-23 may represent a useful immunogen to implement active specific immunotherapy in patients with melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
GREENWOOD, F., HUNTER, W., & GLOVER, J. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,152
Fraker, P. J., & Speck, J. C. (1978) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(78)91322-0 · Cited by 4,558
Peto, R., & Pike, M. C. (1973) · PubMed · Cited by 659
Carcinogenesis—A Comprehensive survey
(1982) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(82)80078-1 · Cited by 335
[8] Use of glutaraldehyde as a coupling agent for proteins and peptides
Reichlin, M. (1980) · Methods in Enzymology · doi:10.1016/s0076-6879(80)70047-2 · Cited by 305
Wilson, B. S., Imai, K., Natali, P. G., & Ferrone, S. (1981) · International Journal of Cancer · doi:10.1002/ijc.2910280307 · Cited by 281
Self-citationReisfeld, R. A., & Cheresh, D. A. (1987) · Advances in immunology · doi:10.1016/s0065-2776(08)60242-4 · Cited by 125
TEMPONI, M., Kageshita, T., Perosa, F., Ono, R., OKADA, H., & Ferrone, S. (1989) · Hybridoma · doi:10.1089/hyb.1989.8.85 · Cited by 122
Self-citation
Cited by
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Self-citationMonoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 307
Self-citationEpigenetic drugs as immunomodulators for combination therapies in solid tumors
Sigalotti, L., Fratta, E., Coral, S., & Maio, M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.015 · Cited by 102
p130Cas: A key signalling node in health and disease
Barrett, A., Pellet-Many, C., Zachary, I. C., Evans, I. M., & Frankel, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.12.019 · Cited by 93
Metadata
- Authors
- Mittelman, A., Chen, Z. J., Yang, H., Wong, G. Y., & Ferrone, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-01-15
- Volume
- 89
- Issue
- 2
- Pages
- 466-470
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2009642161
- Cited by
- 260
- References
- 13
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.